Gene symbol and protein | Gene Location | All allelic disease phenotypes - locus/disease symbols |
| 13q12 | * Autosomal recessive spastic ataxia of Charlevoix-Saguenay - ARSACS (13.94, 14.93, 15.81) * Charcot-Marie-Tooth disease, axonal; related to SACS - (13.94, 14.93, 15.81)
* Spastic ataxia, Charlevoix-Saguenay type - SACS (13.94, 14.93, 15.81)
* Spastic ataxia Charlevoix-Saguenay type - SPAX6 (13.94, 14.93, 15.81)
|
SAMD9LSterile Alpha Motif Domain-Containing Protein 9-Like    | 7q21.2 | * Ataxia-pancytopenia syndrome - ATXPC (13.52)
|
| 22q13.33 | * Charcot-Marie-Tooth neuropathy Type 4B3 - CMT4B3 (14.24)
|
| 11p15.4 | * charcot-marie-tooth disease, type 4b2 - CMT4B2 (14.23)
|
SCN11ASodium voltage-gated channel alpha subunit 11     | 3p22.2 | * Neuropathy, hereditary sensory and autonomic, type VII - HSAN7 (14.107, 14.117)
* Episodic pain syndrome, familial 3 - FEPS3 (14.107, 14.117)
|
SCN1BSodium channel, voltage-gated, type I, beta subunit     | 19q13.11 | * Atrial fibrillation, 13 - ATFB13 (10.158, 10.168)
* Brugada syndrome 5 - BRGDA5 (10.158, 10.168)
|
SCN2BSodium channel, voltage-gated, type II, beta subunit      | 11q23.3 | * Atrial fibrillation, 14 - ATFB14 (10.159)
|
SCN3BSodium channel, voltage-gated, type III, beta subunit     | 11 q24.1 | * Atrial fibrillation, 16 - ATFB16 (10.161, 10.170)
* Brugada syndrome 7 - BRGDA7 (10.161, 10.170)
|
SCN4ASodium channel, voltage-gated, type IV, alpha     | 17q23-q25.3 | * Hyperkalemic periodic paralysis - HYPP (3.61, 7.3, 7.4, 7.6, 7.7, 11.24, 16.32)
* Myotonia potassium-aggravatd - (3.61, 7.3, 7.4, 7.6, 7.7, 11.24, 16.32) * Sodium-channel myasthenia - (3.61, 7.3, 7.4, 7.6, 7.7, 11.24, 16.32)
* Myasthenic syndrome, acetazolamide-responsive - (3.61, 7.3, 7.4, 7.6, 7.7, 11.24, 16.32) * Congenital Myopathy related to SCN4A - (3.61, 7.3, 7.4, 7.6, 7.7, 11.24, 16.32) * Severe foetal hypokinesia related to SCN4A - (3.61, 7.3, 7.4, 7.6, 7.7, 11.24, 16.32)
* Hyperkalemic periodic paralysis, type 2 - HOKPP2 (3.61, 7.3, 7.4, 7.6, 7.7, 11.24, 16.32)
* Paramyotonia congenita of Von Eulenburg - PMC (3.61, 7.3, 7.4, 7.6, 7.7, 11.24, 16.32)
* Potassium-aggravated myotonia - (3.61, 7.3, 7.4, 7.6, 7.7, 11.24, 16.32)
|
SCN4BSodium channel, voltage-gated, type IV, beta subunit     | 11q23.3 | * Atrial fibrillation, 17 - ATFB17 (10.133, 10.162)
* Long QT syndrome 10 - LQT10 (10.133, 10.162)
|
SCN5AVoltage-gated sodium channel type V alpha     | 3p22.2 | * Progressive familial heart block, type I - PFHBI (10.125, 10.154, 10.164, 10.175, 10.41)
* Cardiomyopathy, dilated, 1E - CMD1E (10.125, 10.154, 10.164, 10.175, 10.41)
* Sick Sinus Syndrome 1, autosomal recessive - SSS1 (10.125, 10.154, 10.164, 10.175, 10.41)
* Ventricular fibrillation, idiopathic - IVF (10.125, 10.154, 10.164, 10.175, 10.41)
* Ventricular fibrillation, paroxysmal familial - VF (10.125, 10.154, 10.164, 10.175, 10.41)
* Hereditary bundle branch system defect - HBBD (10.125, 10.154, 10.164, 10.175, 10.41)
* Cardiac conduction defect, progressive - PCCD (10.125, 10.154, 10.164, 10.175, 10.41)
* Brugada syndrome - SCN5A (10.125, 10.154, 10.164, 10.175, 10.41)
* Atrial fibrillation, 10 - ATFB10 (10.125, 10.154, 10.164, 10.175, 10.41)
* Long QT syndrome-3 - LQT3 (10.125, 10.154, 10.164, 10.175, 10.41)
|
SCN9ASodium voltage-gated channel alpha subunit 9     | 2q24.3 | * Neuropathy, hereditary sensory and autonomic, type IID - HSAN2D (14.102, 14.116)
* Erythromelalgia, Primary - SFNP (14.102, 14.116)
|
SCO2Cytochrome c oxidase assembly protein(M)     | 22q13.33 | * Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1 - CEMCOX1 (10.35, 14.92) * Charcot-Marie-Tooth disease, axonal, related to SCO2 - (10.35, 14.92)
|
SCYL1SCY1 like pseudokinase 1     | 11q13.1 | * Spinocerebellar ataxia, autosomal recessive 21 - SCAR21 (13.76)
|
SDHASuccinate dehydrogenase complex, subunit A, flavoprotein (Fp)(M)     | 5p15 | * Recessive neonatal isolated DC - (10.68)
* Cardiomyopathy, dilated, 1GG - CMD1GG (10.68)
|
| 1p36.13 | * Multiminicore disease, classical form - (2.13, 3.16, 3.32, 5.12)
* myopathy, congenital, with fiber-type disproportion - CFTD (2.13, 3.16, 3.32, 5.12) * Rigid spine syndrome related to SEPN1 - RSS (2.13, 3.16, 3.32, 5.12)
* Rigid spine syndrome - RSMD1 (2.13, 3.16, 3.32, 5.12)
* Muscular dystrophy, rigid spine, 1 - RSMD1 (2.13, 3.16, 3.32, 5.12)
* Desmin-related myopathy with Mallory bodies - RSMD1 (2.13, 3.16, 3.32, 5.12)
|
| 17q25 | * Familial brachial plexus neuropathy - HNA (14.122)
|
| 9q34.13 | * Neuropathy, distal hereditary motor, with pyramidal features - ALS4 (12.47, 13.87)
* Spinocerebellar ataxia, autosomal recessive 1 - SCAR1 (12.47, 13.87)
* Spinocerebellar ataxia with axonal neuropathy type 2 - SCAN2 (12.47, 13.87)
|
| 17q21 | * Muscular dystrophy, limb-girdle, type 2D - LGMD2D (1.32)
|
| 4q12 | * Muscular dystrophy, limb-girdle, type 2E - LGMD2E (1.33)
|
| 5q33-q34 | * Dilated Cardiomyopathy, 1L - CMD1L (1.35, 10.47)
* Muscular dystrophy, limb-girdle, type 2F - LGMD2F (1.35, 10.47)
|
| 7q21-q22 | * Myoclonus-dystonia syndrome - DYT11 (16.2)
|
| 13q12 | * Muscular dystrophy, limb-girdle, type 2C - LGMD2C (1.34)
|
SGPL1Sphingosine-1-Phosphate Lyase 1     | 10q22.1 | * Charcot-Marie-Tooth disease, axonal - (14.91)
|
| 5q32 | * Charcot-Marie-Tooth neuropathy Type 4F - CMT4C (14.25)
|
SIGMAR1Sigma non-opioid intracellular receptor 1    | 9p13.3 | * spinal muscular atrophy, distal, autosomal recessive, 2 - DSMA2 (12.6, 12.59)
* Amyotrophic lateral sclerosis 16, juvenile - ALS16 (12.6, 12.59)
|
SIL1SIL1 homolog, endoplasmic reticulum chaperone     | 5q31 | * Marinesco-Sjogren syndrome - MSS (13.89)
|
SLC12A6Potassium chloride cotransporter KCC3     | 15q13-q15 | * Agenesis of the corpus callosum with peripheral neuropathy - ACCPN (14.120)
* Charlevoix disease - SLC12A6 (14.120)
* Andermann syndrome - SLC12A6 (14.120)
|
SLC16A1Solute carrier family 16, member 1 (monocarboxylic acid transporter 1)     | 1p13.2 | * Erythrocyte lactate transporter defect - (9.17)
|
SLC18A3Solute Carrier Family 18 (Vesicular Acetylcholine), Member 3     | 10q11.2 | * Myasthenic Syndrome, Congenital, 21, Presynaptic - CMS21 (11.29)
|
SLC1A3EAAT1 (excitatory amino acid transporter type 1)     | 5p13 | * episodic ataxia type 6 - EA6 (13.48)
|
SLC22A5Solute carrier family 22 member 5     | 5q31 | * Carnitine deficiency, systemic primary - CDSP (9.19)
|
SLC25A1Solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1(M)     | 22q11.21 | * Presynaptic congenital myasthenic syndrome 23 - CMS23 (11.31)
|
SLC25A20Carnitine-acylcarnitine translocase(M)     | 3p21.31 | * Carnitine-acylcarnitine translocase deficiency - CACT (9.20)
|
SLC25A4Mitochondrial carrier; adenine nucleotide translocator(M)     | 4q35 | * Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal - PEOA2 (16.34, 16.54, 16.55)
* Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) - MTDPS12A (16.34, 16.54, 16.55)
* Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) - MTDPS12B (16.34, 16.54, 16.55)
|
SLC25A42Solute carrier family 25 member 42(M)     | 19p13.11 | * Metabolic crises, recurrent, with variable encephalomyopathic features and neurologic regression - MECREN (16.58) * Mitochondrial myopathy - (16.58)
|
SLC25A46solute carrier family 25 member 46(M)     | 5q22.1 | * Neuropathy, hereditary motor and sensory, type VIB - HSMN6B (12.92)
|
SLC33A1Solute carrier family 33 (acetyl- CoA transporter)      | 3q25.3 | * Spastic paraplegia 42, autosomal dominant - SPG42 (15.18)
|
SLC52A2Solute carrier family 52, riboflavin transporter, member 2    | 8q24 | * Brown-Vialetto-Van Laere syndrome 2 - BVVLS2 (12.94)
|
SLC52A3Solute carrier family 52, riboflavin transporter, member 3    | 20p13 | * Brown-Vialetto-Van Laere syndrome 1 - BVVLS1 (12.93)
|
SLC5A7Solute carrier family 5 (sodium/choline cotransporter), member 7     | 2q12.31 | * Motor neuropathy, distal, with vocal cord paralysis - HMN7 (11.28, 12.26)
* Congenital myasthenic syndrome with episodic apnea - CMS20 (11.28, 12.26)
|
SLC9A1Solute carrier family 9, member 1     | 1p36.11 | * Spinocerebellar ataxia, autosomal recessive 19 - SCAR19 (13.74)
|
SLC9A3R1Solute carrier family 9, member 3, regulator 1     | 17q25.1 | * Hereditary peripheral neuropathy - (14.129)
|
SMCHD1Structural maintenance of chromosomes flexible hinge domain containing 1     | 18p11.32 | * Facio-scapulo-humeral muscular dystrophy, type 2 - FSHMD1B (1.11)
|
SMN1Survival of motor neuron 1, telomeric     | 5q13 | * Kugelberg-Welander Syndrome - KWS (12.1, 12.2, 12.3, 12.4)
* Spinal muscular atrophy 4 - SMA4 (12.1, 12.2, 12.3, 12.4)
* Spinal muscular atrophy 2 - SMA2 (12.1, 12.2, 12.3, 12.4)
* Spinal muscular atrophy 3 - SMA3 (12.1, 12.2, 12.3, 12.4)
* Spinal muscular atrophy 1 - SMA1 (12.1, 12.2, 12.3, 12.4)
|
SMPD4Sphingomyelin phosphodiesterase 4, neutral membrane     | 2q21.1 | * Neurodevelopmental disorder with microcephaly, arthrogryposis and structural brain anomalies - NEDMABA (16.25)
|
SMPXSmall Muscle Protein, X-linked     | Xp22.12 | * Distal Myopathy with protein inclusions - (4.27)
|
SNAP25Synaptosome associated protein 25     | 20p12.2 | * Congenital myasthenic syndrome with intellectual disability and ataxia - CMS18 (11.26)
|
| 20q11.21 | * Long QT syndrome 12 - LQT12 (10.135)
|
| 6q14.3 | * Spinocerebellar ataxia, autosomal recessive 20 - SCAR20 (13.75)
|
SOD1Superoxide dismutase 1, soluble     | 21q22.1 | * Amyotrophic lateral sclerosis 1 - ALS1 (12.43, 12.44)
* Amyotrophic lateral sclerosis, due to SOD1 deficiency - ALS (12.43, 12.44)
|
SORDSorbitol Dehydrogenase     | 15q21.1 | * Sorbitol dehydrogenase deficiency with peripheral neuropathy - SORDD (14.94)
|
| 2p24-p21 | * Familial spastic paraplegia, autosomal dominant, 2 - FSP2 (15.2)
* Spastic paraplegia 4 - SPG4 (15.2)
|
| 2q35 | * Centronuclear myopathy with dilated cardiomyopathy - (3.27)
|
SPG11SPG11 vesicle trafficking associated, Spatacsin     | 15q21.1 | * Spastic paraplegia 11 - SPG11 (12.48, 14.89, 15.26)
* Charcot-Marie-Tooth neuropathy Type 2X - CMT2X (12.48, 14.89, 15.26)
* Amyotrophic lateral sclerosis 5 - ALS5 (12.48, 14.89, 15.26)
|
| 13q12.3 | * Spastic paraplegia 20 - SPG20 (15.30)
|
| 15q21-q22 | * Spastic paraplegia 20 - SPG21 (15.31)
|
| 16q24.3 | * Spastic paraplegia 7 - SPG7 (15.24)
|
SPTAN1Spectrin, alpha, nonerythrocytic 1     | 9q34.11 | * Distal motor neuropathy - (12.38)
|
SPTBN2Spectrin, Beta, Nonerythrocytic, 2     | 11q13.2 | * Spinocerebellar ataxia 5 - SCA5 (13.5, 13.69)
* Spinocerebellar ataxia, autosomal recessive 14 - SCAR14 (13.5, 13.69)
|
SPTBN4Spectrin, Beta, Nonerythrocytic, 4     | 19q13 | * Myopathy, Congenital, With Neuropathy And Deafness - CMND (3.51)
|
SPTLC1Serine palmitoyltransferase subunit 1     | 9q22.2 | * Neuropathy, hereditary sensory, type 1 - HSN1 (12.77, 14.97)
* Neuropathy, hereditary sensory and autonomic, type 1 - HSAN1 (12.77, 14.97) * Amyotrophic lateral sclerosis - (12.77, 14.97)
|
SPTLC2Serine palmitoyltransferase long chain base subunit 2     | 14q24.3 | * Neuropathy, hereditary sensory and autonomic, type IC - HSAN1C (14.99)
|
| 5q35.3 | * Amyotrophic lateral sclerosis and/or frontotemporal dementia - FTDALS3 (4.8, 4.21, 12.74)
* Myopathy, distal, with rimmed vacuoles - DMRV (4.8, 4.21, 12.74) * Welander-like distal myopathy - (4.8, 4.21, 12.74)
|
STAC3SH3 and cysteine rich domain 3     | 12q13.3 | * Myopathy, congenital, Bailey-Bloh - MYPBB (3.54, 3.55) * Myopathy, congenital, with malignant hyperthermia susceptibility - (3.54, 3.55)
|
STIM1Stromal interaction molecule 1     | 11p15.4 | * Tubular aggregate myopathy 1 - TAM1 (5.33, 5.39) * Muscle weakness with hyperlaxity, orofacial abnormalities and respiratory infections - (5.33, 5.39)
|
STUB1STIP1 homology and U-box containing protein 1     | 16p13.3 | * Spinocerebellar ataxia, autosomal recessive 16 - SCAR16 (13.44, 13.71)
* Spinocerebellar ataxia 48 - SCA48 (13.44, 13.71)
|
SUCLA2Succinate-CoA ligase, ADP-forming, beta subunit(M)     | 13q12.2-q13.3 | * Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria) - MTDPS5 (16.49)
|
SUCLG1Succinate-CoA ligase, alpha subunit(M)     | 2p11.2 | * Mitochondrial DNA depletion syndrome 9 (Encephalomyopathic type withmethylmalonic aciduria) - MTDPS9 (16.52)
|
| 9q34.2 | * Charcot-Marie-Tooth neuropathy Type 4K - CMT4K (14.33)
|
| 10p11.23 | * Myofibrillar myopathy 10 - MFM10 (5.11)
|
SYNE1Spectrin repeat containing, nuclear envelope 1 (nesprin 1)     | 6q25 | * Dilated cardiomyopathy related to nesprin-1 - (1.6, 10.82, 13.63, 16.21)
* Spinocerebellar ataxia, autosomal recessive 8 - SCAR8 (1.6, 10.82, 13.63, 16.21)
* Emery-dreifuss muscular dystrophy 4 - EDMD4 (1.6, 10.82, 13.63, 16.21)
* Arthrogryposis multiplex congenita with nesprin-1 defect - AMCM (1.6, 10.82, 13.63, 16.21)
|
SYNE2Spectrin repeat containing, nuclear envelope 2 (nesprin 2)     | 14q23.2 | * Nesprin-2 related muscular dystrophy - EDMD (1.7)
|
| 1q32.2 | * Spinocerebellar ataxia, autosomal recessive 11 - SCAR11 (13.66)
|
| 1q32.1 | * Myasthenic syndrome, presynaptic, congenital, with or without motor neuropathy - MYSPC (11.14, 11.15, 12.37) * Distal motor neuropathy related to SYT2 - (11.14, 11.15, 12.37)
* Myasthenic syndrome, congenital, 7B, presynaptic - CMS7B (11.14, 11.15, 12.37)
|